The Association for the Cannabinoid Industry (ACI) is a membership organisation for businesses committed to nurturing a safe, legal and flourishing commercial cannabis extract market in the UK and Europe.
Our vision is to create an innovative and ethical sector with the highest standards of product quality, consumer satisfaction and regulatory compliance. All our members sign up to our quality charter.
We deliver vital stewardship for this emerging sector through constructive engagement with key stakeholders and thought leaders. To find out what we’ve achieved see our list of milestones.
Our team of scientific, regulatory and industry leaders provide expert support and guidance to our members.
ACI in the Media
[Canex] ACI and CMC Recommend 0.03% THC Limit for CBD Products
Canex cover news of the release of our detailed safety review report on THC.
[Analytical Cannabis] The UK Needs A 0.03% THC Limit for CBD Products, Says Industry Group
As outlined in ACI’s report “Health Guidance Levels for THC in CBD products,” the industry group recommend that the UK Home Office enacts a cap of 0.021 mg/kg of THC (and other cannabinol derivatives) per day. This limit would be equivalent to permitting 0.03 percent THC per the recommended 70 mg daily intake of CBD.
[NutraIngredients] Treehouse Biotech submits Novel Foods Application to UK authorities
ACI member Treehouse Biotech has submitted a Novel Foods application to UK authorities for its Cannabidiol (CBD)-based ingredients in a move that signals the US firm’s intent to capture a slice of the UK’s burgeoning CBD market.
[Pharmacy Business Magazine] Industry body welcomes FSA update on CBD products
Pharmacy Business Magazine reports that the FSA updated the criteria for CBD products which can remain on sale from 1 April 2021. Previously, only products which were on sale at the time of the FSA’s announcement (13 February 2020) and were linked to an application which had been validated by 31 March 2021 were to be included.
[Analytical Cannabis] The UK’s Food Standards Agency Updates its CBD Novel Foods Criteria
Last February, the Food Standards Agency (FSA) announced that all CBD businesses operating in England and Wales must have a novel foods application “validated” by March 31, 2021, or risk having their CBD oils, drinks, and treats “taken off the shelves.” Now, with just over two weeks left until the deadline, the FSA has clarified that all applications just have to be “submitted” by March 31, 2021.
[Hemp Grower] CBD Manufacturers Band Together to Sell Products in UK as Deadline Looms
Coverage from the US publication Hemp Grower on the requirement for novel foods applications to sell CBD products in the UK.
[Cannavist] The Food Standards Agency (FSA) has updated its criteria for CBD products to remain on sale after April 1
Previously, only products that were on sale on February 13, 2020 and linked to an application that had been validated by the March 31, 2021 deadline could continue to be sold.
[New Food] Deadline to submit novel food applications for CBD products extended
The criteria for CBD products which can remain on sale from 1 April 2021 has been updated by the Food Standards Agency (FSA).
[NutraIngredients] CBD novel foods deadline delayed amid last minute applications
The FSA has backtracked on its initial expectation for companies to make their novel foods applications at least five weeks in advance of the deadline and confirmed that it will accept applications up until March 31st, after receiving a large number of last minute dossiers.
